Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL36AP12 refers to "ribosomal protein L36a pseudogene 12," which is one of several processed pseudogenes derived from the functional ribosomal protein L36a gene (RPL36A) in the human genome[2][3]. Pseudogenes arise from gene duplications or retrotransposition events and typically lack the ability to encode functional proteins. Like other pseudogenes, RPL36AP12 does not encode a ribosomal protein or any active protein product and is not known to have a direct role as a receptor, enzyme, transporter, or other therapeutic target[2][3]. Some pseudogenes may exert regulatory roles at the RNA level (acting as decoys or regulators of parental gene expression), but there is no specific evidence for functional impact or clinical relevance for RPL36AP12. It is not considered a therapeutic or druggable target and is mainly of genomic, not clinical, interest[2][4].
Not applicable; as a pseudogene, does not encode a functional protein target for drugs
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L36a pseudogene 12 (RPL36AP12).